Assenagon Asset Management
TRVI icon

Assenagon Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Assenagon Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4M Buy
+1,525,314
New +$22.2M 0.04% 334

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Assenagon Asset Management's TRVI Position: Q2 2026 in Review

Assenagon Asset Management opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 1,525,314 shares worth $28.4M. The stake represents 0.04% of the portfolio and ranks #334 among its holdings.

217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Assenagon Asset Management held 1,525,314 shares of Trevi Therapeutics worth $28.4M as of Q2 2026.
  • Trevi Therapeutics was a new Assenagon Asset Management position in Q2 2026.
  • Trevi Therapeutics made up 0.04% of Assenagon Asset Management's portfolio in Q2 2026, its #334 holding.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.